SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

por Goncalves, Joao, Myung, Gihyun, Park, MinJeong, Jeong, Deokyoon, Ghil, Jeehoon
Publicado 2019

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Stasiuk, Barbara, Hilt, Joanna, Mosterova, Zdenka, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

por Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Publicado 2018

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis

por Smolen, Josef S, Choe, Jung-Yoon, Weinblatt, Michael E, Emery, Paul, Keystone, Edward, Genovese, Mark C, Myung, Gihyun, Hong, Evelyn, Baek, Inyoung, Ghil, Jeehoon
Publicado 2020

Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One

por Park, Joseph P., Jung, Byoungin, Park, Hyung Ki, Shin, Donghoon, Jung, Jin Ah, Ghil, Jeehoon, Han, Jihyun, Kim, Kyung Ah, Woollett, Gillian R.
Publicado 2022

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

por Smolen, Josef S., Kang, Young Mo, Yoo, Wan-Hee, Emery, Paul, Weinblatt, Michael E., Keystone, Edward C., Genovese, Mark C., Myung, Gihyun, Baek, Inyoung, Ghil, Jeehoon
Publicado 2020

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M, Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis

por Emery, Paul, Vencovský, Jiří, Sylwestrzak, Anna, Leszczyński, Piotr, Porawska, Wieslawa, Baranauskaite, Asta, Tseluyko, Vira, Zhdan, Vyacheslav M., Stasiuk, Barbara, Milasiene, Roma, Barrera Rodriguez, Aaron Alejandro, Cheong, Soo Yeon, Ghil, Jeehoon
Publicado 2017

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis

por Weinblatt, Michael E., Baranauskaite, Asta, Niebrzydowski, Jaroslaw, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Cheong, Soo Yeon, Ghil, Jeehoon, Sokolovic, S., Mekic, M., Prodanovic, N., Gajic, B., Karaselimovic‐Dzambasovic, E., Pojskic, B., Toncheva, A., Dimitar, P., Rodina, L., Geneva‐Popova, M., Staykov, I., Stoilov, R., Podrazilova, L., Mosterova, Z., Simkova, G., Kopackova, J., Stejfova, Z., Vencovsky, J., Urbanova, Z., Janska, L., Galatíkova, D., Stropuviene, S., Sniuoliene, I., Sitek‐Ziolkowska, K., Rell‐Bakalarska, M., Kolasa, R., Daniluk, S., Sliwowska, B., Bartosik‐Twardowska, M., Brzezicki, J., Konieczny, M., Jeka, S., Choe, J., Bae, S., Kang, Y., Prystupa, L., Vyacheslav, Z., Gasanov, I., Yatsyshyn, R., Rekalov, D., Iaremenko, O., Stanislavchuk, M., Tseluyko, V.
Publicado 2017